developing a portfolio of
oral medicines to transform the patient experience

KalVista is building a pipeline of novel oral, small molecule protease inhibitors through preclinical and clinical development as potential best-in-class treatments for a range of diseases, beginning with hereditary angioedema (HAE).

All our drug programs are internally developed by our R&D team, resulting in full rights and long-term patent protection.